Compare DAKT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | ABUS |
|---|---|---|
| Founded | 1968 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 884.7M |
| IPO Year | 1996 | 2008 |
| Metric | DAKT | ABUS |
|---|---|---|
| Price | $20.13 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 602.4K | ★ 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | $6,171,000.00 |
| Revenue This Year | $13.76 | $125.30 |
| Revenue Next Year | $7.35 | N/A |
| P/E Ratio | $28.07 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $10.95 | $2.71 |
| 52 Week High | $28.27 | $5.10 |
| Indicator | DAKT | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 43.48 |
| Support Level | $18.53 | $4.23 |
| Resistance Level | $20.50 | $4.69 |
| Average True Range (ATR) | 1.12 | 0.23 |
| MACD | -0.75 | -0.03 |
| Stochastic Oscillator | 0.59 | 6.25 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.